Souhaitez-vous accéder aux communiqués récents ?

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS...

MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced...

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary...

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Global Markets for Catheters is expected to grow from $22.8 billion in 2025 to $36 billion by the end of 2030, at a CAGR of 9.6%.

(OTCPK: MAJI) announces several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint.

Dublin, March 05, 2026 (GLOBE NEWSWIRE) -- The "Biosensors - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering.The Biosensors Companies Quadrant is a...

STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of...

EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in...

Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash,...